カテゴリー：世界, 医療/バイオ, QYResearch

代謝性疾患治療薬の世界市場インサイト・予測（～2028年）

【英語タイトル】Global Metabolic Disease Drugs Market Insights, Forecast to 2028
	・商品コード：QY22JLX10411 ・発行会社（調査会社）：QYResearch ・発行日：2022年7月（※2025年版があります。お問い合わせください。）・ページ数：110 ・レポート言語：英語・レポート形式：PDF ・納品方法：Eメール（受注後3営業日）・調査対象地域：グローバル・産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

COVID-19のパンデミックにより、代謝性疾患治療薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に代謝性疾患治療薬の世界市場のxxx％を占める「グリコーゲン代謝病薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
代謝性疾患治療薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの代謝性疾患治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

代謝性疾患治療薬のグローバル主要企業には、Merck、Novartis、Takeda Pharmaceutical、Astra Zeneca、Beohrigher Ingelheim、KOWA、Kythera、Fuji yakuhin、LG Life Science、Metsubishi Tanabe Pharmaなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

代謝性疾患治療薬市場は、種類と用途によって区分されます。世界の代謝性疾患治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
グリコーゲン代謝病薬、脂質代謝病薬、アミノ酸代謝薬、その他

【用途別セグメント】
病院薬局、小売薬局

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 代謝性疾患治療薬製品概要
- 種類別市場（グリコーゲン代謝病薬、脂質代謝病薬、アミノ酸代謝薬、その他）
- 用途別市場（病院薬局、小売薬局）
- 調査の目的
・エグゼクティブサマリー
- 世界の代謝性疾患治療薬販売量予測2017-2028
- 世界の代謝性疾患治療薬売上予測2017-2028
- 代謝性疾患治療薬の地域別販売量
- 代謝性疾患治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別代謝性疾患治療薬販売量
- 主要メーカー別代謝性疾患治療薬売上
- 主要メーカー別代謝性疾患治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（グリコーゲン代謝病薬、脂質代謝病薬、アミノ酸代謝薬、その他）
- 代謝性疾患治療薬の種類別販売量
- 代謝性疾患治療薬の種類別売上
- 代謝性疾患治療薬の種類別価格
・用途別市場規模（病院薬局、小売薬局）
- 代謝性疾患治療薬の用途別販売量
- 代謝性疾患治療薬の用途別売上
- 代謝性疾患治療薬の用途別価格
・北米市場
- 北米の代謝性疾患治療薬市場規模（種類別、用途別）
- 主要国別の代謝性疾患治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの代謝性疾患治療薬市場規模（種類別、用途別）
- 主要国別の代謝性疾患治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の代謝性疾患治療薬市場規模（種類別、用途別）
- 主要国別の代謝性疾患治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の代謝性疾患治療薬市場規模（種類別、用途別）
- 主要国別の代謝性疾患治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの代謝性疾患治療薬市場規模（種類別、用途別）
- 主要国別の代謝性疾患治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Merck、Novartis、Takeda Pharmaceutical、Astra Zeneca、Beohrigher Ingelheim、KOWA、Kythera、Fuji yakuhin、LG Life Science、Metsubishi Tanabe Pharma
・産業チェーン及び販売チャネル分析
- 代謝性疾患治療薬の産業チェーン分析
- 代謝性疾患治療薬の原材料
- 代謝性疾患治療薬の生産プロセス
- 代謝性疾患治療薬の販売及びマーケティング
- 代謝性疾患治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 代謝性疾患治療薬の産業動向
- 代謝性疾患治療薬のマーケットドライバー
- 代謝性疾患治療薬の課題
- 代謝性疾患治療薬の阻害要因
・主な調査結果

Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Market Analysis and Insights: Global Metabolic Disease Drugs Market
The global Metabolic Disease Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Glycogen Metabolism Disease Drug accounting for % of the Metabolic Disease Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Metabolic Disease Drugs market size is valued at US$ million in 2021, while the North America and Europe Metabolic Disease Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Metabolic Disease Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Disease Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Disease Drugs market.
Global Metabolic Disease Drugs Scope and Market Size
Metabolic Disease Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Metabolic Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
By Company
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disease Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global Metabolic Disease Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disease Drugs Market Perspective (2017-2028)
2.2 Metabolic Disease Drugs Growth Trends by Region
2.2.1 Metabolic Disease Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metabolic Disease Drugs Historic Market Size by Region (2017-2022)
2.2.3 Metabolic Disease Drugs Forecasted Market Size by Region (2023-2028)
2.3 Metabolic Disease Drugs Market Dynamics
2.3.1 Metabolic Disease Drugs Industry Trends
2.3.2 Metabolic Disease Drugs Market Drivers
2.3.3 Metabolic Disease Drugs Market Challenges
2.3.4 Metabolic Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disease Drugs Players by Revenue
3.1.1 Global Top Metabolic Disease Drugs Players by Revenue (2017-2022)
3.1.2 Global Metabolic Disease Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Metabolic Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disease Drugs Revenue
3.4 Global Metabolic Disease Drugs Market Concentration Ratio
3.4.1 Global Metabolic Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Drugs Revenue in 2021
3.5 Metabolic Disease Drugs Key Players Head office and Area Served
3.6 Key Players Metabolic Disease Drugs Product Solution and Service
3.7 Date of Enter into Metabolic Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disease Drugs Breakdown Data by Type
4.1 Global Metabolic Disease Drugs Historic Market Size by Type (2017-2022)
4.2 Global Metabolic Disease Drugs Forecasted Market Size by Type (2023-2028)
5 Metabolic Disease Drugs Breakdown Data by Application
5.1 Global Metabolic Disease Drugs Historic Market Size by Application (2017-2022)
5.2 Global Metabolic Disease Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metabolic Disease Drugs Market Size (2017-2028)
6.2 North America Metabolic Disease Drugs Market Size by Type
6.2.1 North America Metabolic Disease Drugs Market Size by Type (2017-2022)
6.2.2 North America Metabolic Disease Drugs Market Size by Type (2023-2028)
6.2.3 North America Metabolic Disease Drugs Market Share by Type (2017-2028)
6.3 North America Metabolic Disease Drugs Market Size by Application
6.3.1 North America Metabolic Disease Drugs Market Size by Application (2017-2022)
6.3.2 North America Metabolic Disease Drugs Market Size by Application (2023-2028)
6.3.3 North America Metabolic Disease Drugs Market Share by Application (2017-2028)
6.4 North America Metabolic Disease Drugs Market Size by Country
6.4.1 North America Metabolic Disease Drugs Market Size by Country (2017-2022)
6.4.2 North America Metabolic Disease Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Metabolic Disease Drugs Market Size (2017-2028)
7.2 Europe Metabolic Disease Drugs Market Size by Type
7.2.1 Europe Metabolic Disease Drugs Market Size by Type (2017-2022)
7.2.2 Europe Metabolic Disease Drugs Market Size by Type (2023-2028)
7.2.3 Europe Metabolic Disease Drugs Market Share by Type (2017-2028)
7.3 Europe Metabolic Disease Drugs Market Size by Application
7.3.1 Europe Metabolic Disease Drugs Market Size by Application (2017-2022)
7.3.2 Europe Metabolic Disease Drugs Market Size by Application (2023-2028)
7.3.3 Europe Metabolic Disease Drugs Market Share by Application (2017-2028)
7.4 Europe Metabolic Disease Drugs Market Size by Country
7.4.1 Europe Metabolic Disease Drugs Market Size by Country (2017-2022)
7.4.2 Europe Metabolic Disease Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disease Drugs Market Size (2017-2028)
8.2 Asia-Pacific Metabolic Disease Drugs Market Size by Type
8.2.1 Asia-Pacific Metabolic Disease Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Metabolic Disease Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Metabolic Disease Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Metabolic Disease Drugs Market Size by Application
8.3.1 Asia-Pacific Metabolic Disease Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Metabolic Disease Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Metabolic Disease Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Metabolic Disease Drugs Market Size by Region
8.4.1 Asia-Pacific Metabolic Disease Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Metabolic Disease Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metabolic Disease Drugs Market Size (2017-2028)
9.2 Latin America Metabolic Disease Drugs Market Size by Type
9.2.1 Latin America Metabolic Disease Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Metabolic Disease Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Metabolic Disease Drugs Market Share by Type (2017-2028)
9.3 Latin America Metabolic Disease Drugs Market Size by Application
9.3.1 Latin America Metabolic Disease Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Metabolic Disease Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Metabolic Disease Drugs Market Share by Application (2017-2028)
9.4 Latin America Metabolic Disease Drugs Market Size by Country
9.4.1 Latin America Metabolic Disease Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Metabolic Disease Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disease Drugs Market Size (2017-2028)
10.2 Middle East & Africa Metabolic Disease Drugs Market Size by Type
10.2.1 Middle East & Africa Metabolic Disease Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Metabolic Disease Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Metabolic Disease Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Metabolic Disease Drugs Market Size by Application
10.3.1 Middle East & Africa Metabolic Disease Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Metabolic Disease Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Metabolic Disease Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Metabolic Disease Drugs Market Size by Country
10.4.1 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Metabolic Disease Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Metabolic Disease Drugs Introduction
11.1.4 Merck Revenue in Metabolic Disease Drugs Business (2017-2022)
11.1.5 Merck Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Metabolic Disease Drugs Introduction
11.2.4 Novartis Revenue in Metabolic Disease Drugs Business (2017-2022)
11.2.5 Novartis Recent Developments
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Details
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Introduction
11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2017-2022)
11.3.5 Takeda Pharmaceutical Recent Developments
11.4 Astra Zeneca
11.4.1 Astra Zeneca Company Details
11.4.2 Astra Zeneca Business Overview
11.4.3 Astra Zeneca Metabolic Disease Drugs Introduction
11.4.4 Astra Zeneca Revenue in Metabolic Disease Drugs Business (2017-2022)
11.4.5 Astra Zeneca Recent Developments
11.5 Beohrigher Ingelheim
11.5.1 Beohrigher Ingelheim Company Details
11.5.2 Beohrigher Ingelheim Business Overview
11.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Introduction
11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2017-2022)
11.5.5 Beohrigher Ingelheim Recent Developments
11.6 KOWA
11.6.1 KOWA Company Details
11.6.2 KOWA Business Overview
11.6.3 KOWA Metabolic Disease Drugs Introduction
11.6.4 KOWA Revenue in Metabolic Disease Drugs Business (2017-2022)
11.6.5 KOWA Recent Developments
11.7 Kythera
11.7.1 Kythera Company Details
11.7.2 Kythera Business Overview
11.7.3 Kythera Metabolic Disease Drugs Introduction
11.7.4 Kythera Revenue in Metabolic Disease Drugs Business (2017-2022)
11.7.5 Kythera Recent Developments
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Company Details
11.8.2 Fuji yakuhin Business Overview
11.8.3 Fuji yakuhin Metabolic Disease Drugs Introduction
11.8.4 Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2017-2022)
11.8.5 Fuji yakuhin Recent Developments
11.9 LG Life Science
11.9.1 LG Life Science Company Details
11.9.2 LG Life Science Business Overview
11.9.3 LG Life Science Metabolic Disease Drugs Introduction
11.9.4 LG Life Science Revenue in Metabolic Disease Drugs Business (2017-2022)
11.9.5 LG Life Science Recent Developments
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Company Details
11.10.2 Metsubishi Tanabe Pharma Business Overview
11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Introduction
11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2017-2022)
11.10.5 Metsubishi Tanabe Pharma Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Metabolic Disease Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Glycogen Metabolism Disease Drug
Table 3. Key Players of Lipid Metabolism Disease Drug
Table 4. Key Players of Amino Acid Metabolism Drug
Table 5. Key Players of Other
Table 6. Global Metabolic Disease Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Metabolic Disease Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Metabolic Disease Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Metabolic Disease Drugs Market Share by Region (2017-2022)
Table 10. Global Metabolic Disease Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Metabolic Disease Drugs Market Share by Region (2023-2028)
Table 12. Metabolic Disease Drugs Market Trends
Table 13. Metabolic Disease Drugs Market Drivers
Table 14. Metabolic Disease Drugs Market Challenges
Table 15. Metabolic Disease Drugs Market Restraints
Table 16. Global Metabolic Disease Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Metabolic Disease Drugs Revenue Share by Players (2017-2022)
Table 18. Global Top Metabolic Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2021)
Table 19. Ranking of Global Top Metabolic Disease Drugs Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Metabolic Disease Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metabolic Disease Drugs Product Solution and Service
Table 23. Date of Enter into Metabolic Disease Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Metabolic Disease Drugs Revenue Market Share by Type (2017-2022)
Table 27. Global Metabolic Disease Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Metabolic Disease Drugs Revenue Market Share by Type (2023-2028)
Table 29. Global Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Metabolic Disease Drugs Revenue Share by Application (2017-2022)
Table 31. Global Metabolic Disease Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Metabolic Disease Drugs Revenue Share by Application (2023-2028)
Table 33. North America Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Metabolic Disease Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Metabolic Disease Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Metabolic Disease Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Metabolic Disease Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Metabolic Disease Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Metabolic Disease Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Metabolic Disease Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Metabolic Disease Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Metabolic Disease Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Metabolic Disease Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Metabolic Disease Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Metabolic Disease Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Metabolic Disease Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Metabolic Disease Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Metabolic Disease Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Metabolic Disease Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Metabolic Disease Drugs Product
Table 66. Merck Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 67. Merck Recent Developments
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Metabolic Disease Drugs Product
Table 71. Novartis Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 72. Novartis Recent Developments
Table 73. Takeda Pharmaceutical Company Details
Table 74. Takeda Pharmaceutical Business Overview
Table 75. Takeda Pharmaceutical Metabolic Disease Drugs Product
Table 76. Takeda Pharmaceutical Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 77. Takeda Pharmaceutical Recent Developments
Table 78. Astra Zeneca Company Details
Table 79. Astra Zeneca Business Overview
Table 80. Astra Zeneca Metabolic Disease Drugs Product
Table 81. Astra Zeneca Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 82. Astra Zeneca Recent Developments
Table 83. Beohrigher Ingelheim Company Details
Table 84. Beohrigher Ingelheim Business Overview
Table 85. Beohrigher Ingelheim Metabolic Disease Drugs Product
Table 86. Beohrigher Ingelheim Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 87. Beohrigher Ingelheim Recent Developments
Table 88. KOWA Company Details
Table 89. KOWA Business Overview
Table 90. KOWA Metabolic Disease Drugs Product
Table 91. KOWA Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 92. KOWA Recent Developments
Table 93. Kythera Company Details
Table 94. Kythera Business Overview
Table 95. Kythera Metabolic Disease Drugs Product
Table 96. Kythera Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 97. Kythera Recent Developments
Table 98. Fuji yakuhin Company Details
Table 99. Fuji yakuhin Business Overview
Table 100. Fuji yakuhin Metabolic Disease Drugs Product
Table 101. Fuji yakuhin Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 102. Fuji yakuhin Recent Developments
Table 103. LG Life Science Company Details
Table 104. LG Life Science Business Overview
Table 105. LG Life Science Metabolic Disease Drugs Product
Table 106. LG Life Science Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 107. LG Life Science Recent Developments
Table 108. Metsubishi Tanabe Pharma Company Details
Table 109. Metsubishi Tanabe Pharma Business Overview
Table 110. Metsubishi Tanabe Pharma Metabolic Disease Drugs Product
Table 111. Metsubishi Tanabe Pharma Revenue in Metabolic Disease Drugs Business (2017-2022) & (US$ Million)
Table 112. Metsubishi Tanabe Pharma Recent Developments
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disease Drugs Market Share by Type: 2021 VS 2028
Figure 2. Glycogen Metabolism Disease Drug Features
Figure 3. Lipid Metabolism Disease Drug Features
Figure 4. Amino Acid Metabolism Drug Features
Figure 5. Other Features
Figure 6. Global Metabolic Disease Drugs Market Share by Application: 2021 VS 2028
Figure 7. Hospital Pharmacy Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Metabolic Disease Drugs Report Years Considered
Figure 10. Global Metabolic Disease Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Metabolic Disease Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Metabolic Disease Drugs Market Share by Region: 2021 VS 2028
Figure 13. Global Metabolic Disease Drugs Market Share by Players in 2021
Figure 14. Global Top Metabolic Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Metabolic Disease Drugs Revenue in 2021
Figure 16. North America Metabolic Disease Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Metabolic Disease Drugs Market Size Market Share by Type (2017-2028)
Figure 18. North America Metabolic Disease Drugs Market Size Market Share by Application (2017-2028)
Figure 19. North America Metabolic Disease Drugs Market Size Share by Country (2017-2028)
Figure 20. United States Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Metabolic Disease Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Metabolic Disease Drugs Market Size Market Share by Type (2017-2028)
Figure 24. Europe Metabolic Disease Drugs Market Size Market Share by Application (2017-2028)
Figure 25. Europe Metabolic Disease Drugs Market Size Share by Country (2017-2028)
Figure 26. Germany Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Metabolic Disease Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Metabolic Disease Drugs Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Metabolic Disease Drugs Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Metabolic Disease Drugs Market Size Share by Region (2017-2028)
Figure 36. China Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America Metabolic Disease Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Metabolic Disease Drugs Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Metabolic Disease Drugs Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Metabolic Disease Drugs Market Size Share by Country (2017-2028)
Figure 46. Mexico Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Metabolic Disease Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Metabolic Disease Drugs Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Metabolic Disease Drugs Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Metabolic Disease Drugs Market Size Share by Country (2017-2028)
Figure 52. Turkey Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Metabolic Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Merck Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 56. Novartis Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 57. Takeda Pharmaceutical Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 58. Astra Zeneca Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 59. Beohrigher Ingelheim Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 60. KOWA Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 61. Kythera Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 62. Fuji yakuhin Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 63. LG Life Science Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 64. Metsubishi Tanabe Pharma Revenue Growth Rate in Metabolic Disease Drugs Business (2017-2022)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

★調査レポート[代謝性疾患治療薬の世界市場インサイト・予測（～2028年）] (コード：QY22JLX10411)販売に関する免責事項を必ずご確認ください。

★調査レポート[代謝性疾患治療薬の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ

MarketReport.jp

代謝性疾患治療薬の世界市場インサイト・予測（～2028年）

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp